成纤维细胞激活蛋白靶向放射性配体治疗用于实体瘤治疗
该研究分析34例人乳腺癌、卵巢癌、结直肠癌和肺癌单细胞RNA测序数据,发现约5%的细胞过表达FAP,其中癌症相关成纤维细胞占该FAP阳性亚群的约77%、癌细胞约占2%。作者合成FAP6-DOTA偶联物并加用白蛋白结合剂IP,在4种小鼠肿瘤模型中评估其药代动力学与放射治疗效力。177Lu-FAP6-IP-DOTA的肿瘤剂量较177Lu-FAP6-DOTA高88倍,单次给药使所有受试肿瘤模型的肿瘤生长抑制约45%,未引起可重复的毒性。
要点
- 人肿瘤中约5%的细胞过表达FAP,其中癌症相关成纤维细胞约占77%、癌细胞约占2%。
- 177Lu-FAP6-IP-DOTA的肿瘤剂量较177Lu-FAP6-DOTA高88倍,并改善所有肿瘤与健康器官比值。
- 单次177Lu-FAP6-IP-DOTA使所有受试肿瘤模型肿瘤生长抑制约45%,未引起可重复毒性。
核心结论
- 作者认为177Lu-FAP6-IP-DOTA是实体瘤FAP靶向放射性配体治疗的有前景候选药物。
研究设计与样本
- 分析34例人乳腺癌、卵巢癌、结直肠癌和肺癌的单细胞RNA测序数据以定量FAP过表达细胞。
- 合成含或不含白蛋白结合剂IP的FAP6-DOTA偶联物,并检测其与人FAP表达细胞的结合。
- 在KB、HT29、U87MG和4T1小鼠肿瘤模型中,通过放射成像或生物分布分析评估111In或177Lu标记偶联物的蓄积。
- 通过测量肿瘤体积随时间变化定量放射治疗效力。
主要发现
- 人肿瘤中约5%的所有细胞过表达FAP,癌症相关成纤维细胞占该FAP阳性亚群的约77%,癌细胞约占2%。
- FAP6偶联物以高亲和力结合FAP表达细胞,解离常数约1 nM。
- 177Lu-FAP6-IP-DOTA的肿瘤剂量较177Lu-FAP6-DOTA高88倍,并改善所有肿瘤与健康器官比值。
- 单次177Lu-FAP6-IP-DOTA在所有受试肿瘤模型中使肿瘤生长抑制约45%,未引起可重复的毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) has received increasing attention as an oncologic target because of its prominent expression in solid tumors but virtual absence from healthy tissues. Most radioligand therapies (RLTs) targeting FAP, however, suffer from inadequate tumor retention or clearance from healthy tissues. Herein we report a FAP-targeted RLT comprising an FAP6 ligand conjugated to DOTA and an albumin binder (4-p-iodophenylbutyric acid, or IP) for enhanced pharmacokinetics. We evaluated the performance of the resulting FAP6-IP-DOTA conjugate in 4 tumor models, 3 of which express FAP only on cancer-associated fibroblasts, that is, analogously to human tumors. Methods: Single-cell RNA-sequencing data were analyzed from 34 human breast, ovarian, colorectal, and lung cancers to quantify FAP-overexpressing cells. FAP6-DOTA conjugates were synthesized with or without an albumin binder (IP) and investigated for binding to human FAP-expressing cells. Accumulation of 111In- or 177Lu-labeled conjugates in KB, HT29, U87MG, and 4T1 murine tumors was also assessed by radioimaging or biodistribution analyses. Radiotherapeutic potency was quantitated by measuring tumor volumes versus time. Results: Approximately 5% of all cells in human tumors overexpressed FAP (cancer-associated fibroblasts comprised ∼77% of this FAP-positive subpopulation, whereas ∼2% were cancer cells). FAP6 conjugates bound to FAP-expressing cells with high affinity (dissociation constant, ∼1 nM). 177Lu-FAP6-IP-DOTA achieved an 88-fold higher tumor dose than 177Lu-FAP6-DOTA and improved all tumor-to-healthy-organ ratios. Single doses of 177Lu-FAP6-IP-DOTA suppressed tumor growth by about 45% in all tested tumor models without causing reproducible toxicities. Conclusion: We conclude that 177Lu-FAP6-IP-DOTA constitutes a promising candidate for FAP-targeted RLT of solid tumors.
引用
- Lindeman SD, Mukkamala R, Horner A, et al. Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors. J Nucl Med. 2022. PMID: 37116911. doi:10.2967/jnumed.122.264494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。